Prevalence of cardiac amyloidosis in atrial fibrillation: a CMR study prior to catheter ablation.
Atrial fibrillation
Cardiac amyloidosis
Cardiac magnetic resonance
T1 mapping
Journal
Heart and vessels
ISSN: 1615-2573
Titre abrégé: Heart Vessels
Pays: Japan
ID NLM: 8511258
Informations de publication
Date de publication:
29 Jul 2024
29 Jul 2024
Historique:
received:
05
06
2024
accepted:
24
07
2024
medline:
29
7
2024
pubmed:
29
7
2024
entrez:
29
7
2024
Statut:
aheadofprint
Résumé
The frequency of cardiac amyloidosis potentially present in patients with atrial fibrillation (AF) remains unclear. The purpose of this study is to determine the frequency and clinical characteristics of cardiac amyloidosis latent in AF by performing cardiac magnetic resonance imaging (MRI) in patients scheduled for AF ablation. We retrospectively analyzed 193 consecutive patients who underwent CA and cardiac MRI for atrial fibrillation. The primary endpoint of the study was the frequency of histologically confirmed cardiac amyloidosis or suspected cardiac amyloidosis [positive imaging findings on cardiac MRI strongly suspecting cardiac amyloidosis (diffuse subendocardial late gadolinium enhancement or MRI-derived extracellular volume of > 0.40)]. Among the 193 patients, 8 were confirmed or suspected cases of cardiac amyloidosis, representing a frequency of 4% (8/193 patients). Multivariate analysis identified interventricular septal thickness at end-diastole (LVSd) as an independent and significant predictor of cardiac amyloidosis (OR: 1.72, 95% CI 1.12-2.87, p = 0.020).The optimal cut-off value for IVSd was determined to be > 12.9 mm based on the Youden index. At this cut-off, the sensitivity was 75.0% (95% CI 34.9-96.8%) and the specificity was 92.3% (95% CI 87.4-95.7%), allowing for the identification of patients with definite or suspected cardiac amyloidosis. The frequency of confirmed and suspected cases of cardiac amyloidosis among patients with an IVSd > 12.9 mm was 30% (6/20 patients). In addition, prevalence of biopsy-proven cardiac amyloidosis was 10% (2/20). The prevalence of cardiac amyloidosis in atrial fibrillation patients scheduled for ablation with cardiac hypertrophy is not negligible.
Identifiants
pubmed: 39073423
doi: 10.1007/s00380-024-02447-w
pii: 10.1007/s00380-024-02447-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Springer Nature Japan KK, part of Springer Nature.
Références
Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, Deswal A, Eckhardt LL, Goldberger ZD, Gopinathannair R, Gorenek B, Hess PL, Hlatky M, Hogan G, Ibeh C, Indik JH, Kido K, Kusumoto F, Link MS, Linta KT, Marcus GM, McCarthy PM, Patel N, Patton KK, Perez MV, Piccini JP, Russo AM, Sanders P, Streur MM, Thomas KL, Times S, Tisdale JE, Valente AM, Van Wagoner DR (2024) 2023 ACC/AHA/ACCP/HRS Guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 149(1):e1–e156
doi: 10.1161/CIR.0000000000001193
pubmed: 38033089
Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, Merkely B, Pokushalov E, Sanders P, Proff J, Schunkert H, Christ H, Vogt J, Bänsch D (2018) Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 378(5):417–427
doi: 10.1056/NEJMoa1707855
pubmed: 29385358
Hartnett J, Jaber W, Maurer M, Sperry B, Hanna M, Collier P, Patel DR, Wazni OM, Donnellan E (2021) Electrophysiological manifestations of cardiac amyloidosis: JACC: cardiooncology state-of-the-art review. JACC CardioOncol 3(4):506–515
doi: 10.1016/j.jaccao.2021.07.010
pubmed: 34729522
pmcid: 8543134
Argirò A, Del Franco A, Mazzoni C, Allinovi M, Tomberli A, Tarquini R, Di Mario C, Perfetto F, Cappelli F, Zampieri M (2022) Arrhythmic burden in cardiac amyloidosis: what we know and what we do not. Biomedicines 10(11):2888
doi: 10.3390/biomedicines10112888
pubmed: 36359408
pmcid: 9687719
Briasoulis A, Kourek C, Papamichail A, Loritis K, Bampatsias D, Repasos E, Xanthopoulos A, Tsougos E, Paraskevaidis I (2023) Arrhythmias in patients with cardiac amyloidosis: a comprehensive review on clinical management and devices. J Cardiovasc Dev Dis 10(8):337
pubmed: 37623350
pmcid: 10455774
Haaf P, Garg P, Messroghli DR, Broadbent DA, Greenwood JP, Plein S (2016) Cardiac T1 mapping and Extracellular Volume (ECV) in clinical practice: a comprehensive review. J Cardiovasc Magn Reson 18(1):89
doi: 10.1186/s12968-016-0308-4
pubmed: 27899132
pmcid: 5129251
Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ (2005) Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J 26(15):1461–1474
doi: 10.1093/eurheartj/ehi258
pubmed: 15831557
Alwan L, Benz DC, Cuddy SAM, Dobner S, Shiri I, Caobelli F, Bernhard B, Stämpfli SF, Eberli F, Reyes M, Kwong RY, Falk RH, Dorbala S, Gräni C (2023) Current and evolving multimodality cardiac imaging in managing transthyretin amyloid cardiomyopathy. JACC Cardiovasc Imag 17(2):195–211
doi: 10.1016/j.jcmg.2023.10.010
Pan JA, Kerwin MJ, Salerno M (2020) Native T1 mapping, extracellular volume mapping, and late gadolinium enhancement in cardiac amyloidosis: a meta-analysis. JACC Cardiovasc Imag 13(6):1299–1310
doi: 10.1016/j.jcmg.2020.03.010
Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM, Maestrini V, Barcella W, Rosmini S, Bulluck H, Sayed RH, Patel K, Mamhood S, Bucciarelli-Ducci C, Whelan CJ, Herrey AS, Lachmann HJ, Wechalekar AD, Manisty CH, Schelbert EB, Kellman P, Gillmore JD, Hawkins PN, Moon JC (2015) Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 132(16):1570–1579
doi: 10.1161/CIRCULATIONAHA.115.016567
pubmed: 26362631
pmcid: 4606985
Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, Bezzina CR, Biagini E, Blom NA, de Boer RA, De Winter T, Elliott PM, Flather M, Garcia-Pavia P, Haugaa KH, Ingles J, Jurcut RO, Klaassen S, Limongelli G, Loeys B, Mogensen J, Olivotto I, Pantazis A, Sharma S, Van Tintelen JP, Ware JS, Kaski JP (2023) 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J 44(37):3503–3626
doi: 10.1093/eurheartj/ehad194
pubmed: 37622657
Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379(11):1007–1016
doi: 10.1056/NEJMoa1805689
pubmed: 30145929
Ichikawa Y, Oota E, Odajima S, Kintsu M, Todo S, Takeuchi K, Yamauchi Y, Shiraki H, Yamashita K, Fukuda T, Hisamatsu E, Hirata KI, Tanaka H (2023) Impact of tafamidis on echocardiographic cardiac function of patients with transthyretin cardiac amyloidosis. Circ J 87(4):508–516
doi: 10.1253/circj.CJ-22-0683
pubmed: 36878601
Achten A, van Empel VPM, Weerts J, Mourmans S, Beckers-Wesche F, Spanjers M, Gingele A, Brunner-La Rocca HP, Sanders-van Wijk S, Knackstedt C (2024) Changes in the diagnostic trajectory of transthyretin cardiac amyloidosis over six years. Heart Vessels. https://doi.org/10.1007/s00380-024-02408-3
doi: 10.1007/s00380-024-02408-3
pubmed: 38710807
Shibata A, Izumiya Y, Yoshida T, Tanihata A, Yamaguchi Y, Kitada R, Fukuda D (2024) Elevation of end-tidal CO(2) during exercise is attenuated in patients with cardiac amyloidosis. Heart Vessels 39(4):340–348
doi: 10.1007/s00380-023-02342-w
pubmed: 38105354
Zhu Y, Yuan H, Qu H (2024) Serum alpha 1 antitrypsin potent act as an early diagnostic biomarker for cardiac amyloidosis. Heart Vessels. https://doi.org/10.1007/s00380-024-02396-4
doi: 10.1007/s00380-024-02396-4
pubmed: 38580850
Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, Fontana M, Gheysens O, Gillmore JD, Glaudemans A, Hanna MA, Hazenberg BPC, Kristen AV, Kwong RY, Maurer MS, Merlini G, Miller EJ, Moon JC, Murthy VL, Quarta CC, Rapezzi C, Ruberg FL, Shah SJ, Slart R, Verberne HJ, Bourque JM (2021) ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. Circ Cardiovasc Imag 14(7):e000029
Hahn VS, Yanek LR, Vaishnav J, Ying W, Vaidya D, Lee YZJ, Riley SJ, Subramanya V, Brown EE, Hopkins CD, Ononogbu S, Perzel Mandell K, Halushka MK, Steenbergen C Jr, Rosenberg AZ, Tedford RJ, Judge DP, Shah SJ, Russell SD, Kass DA, Sharma K (2020) Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis. JACC Heart Fail 8(9):712–724
doi: 10.1016/j.jchf.2020.04.007
pubmed: 32653448
pmcid: 7604801
Castaño A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A, Rubin J, Chiuzan C, Nazif T, Vahl T, George I, Kodali S, Leon MB, Hahn R, Bokhari S, Maurer MS (2017) Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J 38(38):2879–2887
doi: 10.1093/eurheartj/ehx350
pubmed: 29019612
pmcid: 5837725
Wang J, Chen H, Tang Z, Zhang J, Xu Y, Wan K, Hussain K, Gkoutos GV, Han Y, Chen Y (2023) Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis. EClinicalMedicine 63:102172
doi: 10.1016/j.eclinm.2023.102172
pubmed: 37662524
pmcid: 10474377
Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, Rowczenio DM, Gilbertson JA, Hutt DF, Rezk T, Strehina SG, Caringal-Galima J, Manwani R, Sharpley FA, Wechalekar AD, Lachmann HJ, Mahmood S, Sachchithanantham S, Drage EPS, Jenner HD, McDonald R, Bertolli O, Calleja A, Hawkins PN, Gillmore JD (2019) Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation 140(1):16–26
doi: 10.1161/CIRCULATIONAHA.118.038169
pubmed: 31109193
Ochi Y, Kubo T, Baba Y, Sugiura K, Miyagawa K, Noguchi T, Hirota T, Hamada T, Yamasaki N, Kitaoka H (2022) Early experience of tafamidis treatment in japanese patients with wild-type transthyretin cardiac amyloidosis from the kochi amyloidosis cohort. Circ J 86(7):1121–1128
doi: 10.1253/circj.CJ-21-0965
pubmed: 35599003
Rettl R, Mann C, Duca F, Dachs TM, Binder C, Ligios LC, Schrutka L, Dalos D, Koschutnik M, Donà C, Kammerlander A, Beitzke D, Loewe C, Charwat-Resl S, Hengstenberg C, Kastner J, Eslam RB, Bonderman D (2022) Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy. Eur Heart J Cardiovasc Imag 23(6):767–780
doi: 10.1093/ehjci/jeab226
Garcia-Pavia P, Aus dem Siepen F, Donal E, Lairez O, van der Meer P, Kristen AV, Mercuri MF, Michalon A, Frost RJA, Grimm J, Nitsch RM, Hock C, Kahr PC, Damy T (2023) Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid. N Engl J Med 389(3):239–250
doi: 10.1056/NEJMoa2303765
pubmed: 37212440
Takashio S, Morioka M, Ishii M, Morikawa K, Hirakawa K, Hanatani S, Oike F, Usuku H, Kidoh M, Oda S, Yamamoto E, Matsushita K, Ueda M, Tsujita K (2023) Clinical characteristics, outcome, and therapeutic effect of tafamidis in wild-type transthyretin amyloid cardiomyopathy. ESC Heart Fail 10(4):2319–2329
doi: 10.1002/ehf2.14380
pubmed: 37073415
pmcid: 10375127
Tsai CH, Chao CC, Hsieh ST, Yu AL, Wu YA, Cheng MF, Lee MJ, Chou CH, Shun CT, Hsueh HW, Jyh-Ming Juang J, Tseng PH, Su MY, Lin YH (2023) Tafamidis decreased cardiac amyloidosis deposition in patients with Ala97Ser hereditary transthyretin cardiomyopathy: a 12-month follow-up cohort study. Orphanet J Rare Dis 18(1):289
doi: 10.1186/s13023-023-02824-0
pubmed: 37705003
pmcid: 10498629
Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol 79(4):319–328
doi: 10.1002/ajh.20381
pubmed: 16044444
Kato S, Misumi Y, Horita N, Yamamoto K, Utsunomiya D (2023) Clinical utility of computed tomography-derived myocardial extracellular volume fraction: a systematic review and meta-analysis. JACC Cardiovasc Imaging 17(5):516–528
doi: 10.1016/j.jcmg.2023.10.008
pubmed: 37999657
Zhang H, Guo H, Liu G, Wu C, Ma Y, Li S, Zheng Y, Zhang J (2023) CT for the evaluation of myocardial extracellular volume with MRI as reference: a systematic review and meta-analysis. Eur Radiol 33(12):8464–8476
doi: 10.1007/s00330-023-09872-x
pubmed: 37378712
Kidoh M, Oda S, Takashio S, Hirakawa K, Kawano Y, Shiraishi S, Hayashi H, Nakaura T, Nagayama Y, Funama Y, Ueda M, Tsujita K, Hirai T (2023) CT extracellular volume fraction versus myocardium-to-lumen signal ratio for cardiac amyloidosis. Radiology 306(3):e220542
doi: 10.1148/radiol.220542
pubmed: 36255307
Yamasaki H, Kondo H, Shiroo T, Iwata N, Masuda T, Makita T, Iwabuchi Y, Tanazawa K, Takahashi M, Ono Y, Ogawa N, Harada T, Mitarai K, Yamauchi S, Takano M, Kodama N, Hirota K, Miyoshi M, Yonezu K, Tawara K, Abe I, Saito S, Fukui A, Fukuda T, Akioka H, Shinohara T, Akiyoshi K, Teshima Y, Yufu K, Daa T, Matsubara E, Asayama Y, Ueda M, Takahashi N (2024) Efficacy of computed tomography-based evaluation of myocardial extracellular volume combined with red flags for early screening of concealed cardiac amyloidosis in patients with atrial fibrillation. Circ J 88(7):1167–1175
doi: 10.1253/circj.CJ-23-0948
pubmed: 38522901
Kanazawa H, Takashio S, Hoshiyama T, Ito M, Kaneko S, Kiyama T, Kawahara Y, Sumi H, Tsuruta Y, Kuyama N, Hirakawa K, Ishii M, Tabata N, Yamanaga K, Fujisue K, Hanatani S, Sueta D, Arima Y, Araki S, Matsuzawa Y, Usuku H, Nakamura T, Yamamoto E, Soejima H, Matsushita K, Tsujita K (2024) Clinical outcomes of catheter ablation for atrial fibrillation, atrial flutter, and atrial tachycardia in wild-type transthyretin amyloid cardiomyopathy: a proposed treatment strategy for catheter ablation in each arrhythmia. Europace 26(6):155
doi: 10.1093/europace/euae155